The Latest Breaking News from gene editing

A new study from Stanford Medicine shows how a gene editing tool identified a gene to knock out that could promote activation of neural stem cells.

A geneticist recently discovered the gene that accounts for prickliness across a variety of plants, including roses.

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

Explore the potential of genetic enhancements in humans for space travel and the ethical considerations surrounding gene editing technology.

Tuberculosis dates back more than 9,000 years. It is the most infectious bacterial disease and in 2022 10.6 million people fell ill with it. Of these 23% occurred in Africa.

Scientists are pursuing advances to address the technology's limitations and stretch gene editing to treat different types of diseases, improve agriculture, livestock and more.

During her chemistry Nobel Prize lecture in 2018, Frances Arnold said, “Today we can for all practical purposes read, write and edit any sequence of DNA, but we cannot compose it.” That isn’t true anymore.

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

The biotechnology industry is thriving, fueled by solid government support, rising healthcare spending worldwide, gene editing breakthroughs, and rapid AI adoption. Hence, fundamentally solid biotech stocks Shionogi (SGIOY), United Therapeutics (UTHR), and SIGA Technologies (SIGA) could be ideal buys for potential gains. Keep reading….